Management of Central Giant Cell Granuloma with Subcutaneous Denosumab Therapy

January 29th, 2015

Central giant cell granuloma is a rare, aggressive lesion that occurs almost exclusively in the mandible, with treatment traditionally focused on inhibiting osteoclasts, which are responsible for absorbing bone.

An article published in the December 2014 issue of the Journal of Oral and Maxillofacial Surgery is the result of collaboration between the departments of diagnostic sciences and oral and maxillofacial surgery and demonstrates the viability of monthly injections of denosumab in place of or in addition to surgery. In both case studies, lesion size decreased, and facial symmetry and bone contour improved. Long-term implications may mean less extensive surgical intervention and lowered morbidity rates associated with treatment of this condition.

Citation: Naidu A; Malmquist M, Denham C, Schow SR. Management of Central Giant Cell Granuloma with Subcutaneous Denosumab Therapy. Journal of Oral and Maxillofacial Surgery December 2014, 72(12):2469-2484.

— Jennifer Fuentes